TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02457676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert Program for Self-Regulation
Description: Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations.
Study: NCT02430064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low PAMP diet
Study: NCT02593331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFKB8488A
Description: Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
Study: NCT02829749

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: traditional mitral valve repair performed under cardiac arrest
Study: NCT00254995

Intervention type: BIOLOGICAL
Intervention: None administered in this study
Description: N/A in this study

Intervention type: BIOLOGICAL
Intervention: None administered in this study
Description: N/A in this study
Study: NCT02547662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT04182035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient-tailored therapy
Description: The subjects in the PTT group will receive the individual tailored treatment program combining best evidence active and passive treatment strategies (manual therapy, individual exercises) in combination with education tailored to the individual situation of the patient and selected home exercises. 9 individual therapy sessions will be performed, in combination with 9 additional home exercise sessions.. NRS and NDI-scores will be monitored before every treatment. The therapist will register when the cut-off score of 30% NDI reduction is present in order to determine the evolution in pain/disability reduction. The importance of self-efficacy will be emphasized and tailored home-exercises will be monitored and adjusted every week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-patient tailored therapy: generalized exercise program
Description: The NPTT will receive an individual (hands-off) treatment, which includes an active neck exercise program, non-tailored education and non-tailored home exercises, according to a previously published program with good results.53 The sessions will be performed once a week under supervision (9 therapy sessions, standard exercise program) and once a week by the patient at home (9 home exercise sessions, standard exercise program).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education considering neck pain information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education considering neck pain information
Study: NCT01911507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study: NCT02789176

Intervention type: OTHER
Intervention: Surveys
Description: Regarding development, epilepsy, and family impact
Study: NCT02593331

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo on Day 1.
Study: NCT02789176

Intervention type: OTHER
Intervention: Surveys
Description: Regarding development, epilepsy, and family impact

Intervention type: OTHER
Intervention: EEG
Study: NCT00733720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone
Description: 4/1mg, 8/2mg 16/4mg
Study: NCT01024543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT03395366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multifaceted Educational / Cognitive Behavioral Intervention
Description: The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts \& worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
Study: NCT01654965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT02693574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study: NCT03571087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL140 5/10
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT03199989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CapeOX（Capecitabine+Oxaliplatin）
Description: Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
Study: NCT02181543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
Study: NCT03135873

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mastiha
Description: Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is designed to have identical characteristics with verum.
Study: NCT01355380

Intervention type: DRUG
Intervention: Inhaled iloprost (Ventavis, BAYQ6256)
Description: Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
Study: NCT03093480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
Study: NCT03701971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of the intensity of pruritus
Description: evaluation of the intensity of pruritus with various questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: evaluation of the intensity of pruritus
Description: evaluation of the intensity of pruritus with various questionnaires
Study: NCT03057769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papillary epinephrine spraying
Description: All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Papillary saline spraying
Description: All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indomethacin
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Study: NCT04249934

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeinated Coffee
Description: A single 8 ounce cup of regular starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DecaffeinatedCoffee
Description: A single 8 ounce cup of decaffeinated starbucks coffee will be given to the participant in the am post operative day two. Participants will have 15 minutes to consume the coffee. Additionally, medical record data will be collected up to 30 days after surgery.
Study: NCT03321773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple therapy plus bismuth therapy
Description: pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reverse hybrid therapy
Description: (pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
Study: NCT03380091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral medication daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral medication daily
Study: NCT03571087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL140 10/10
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL140 20/10
Description: 1) Treatment(W0\~W8), Extension(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg → HL140 5/10
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~   * HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg → HL140 10/10
Description: 1. Treatment(W0\~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~2. Extension period(W9\~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~   * HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg → HL140 20/10
Description: 1. Treatment(W0\~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~   ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~2. Extension period(W9\~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo
Study: NCT01963390

Intervention type: DRUG
Intervention: Testosterone Therapy
Description: In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
Study: NCT02170584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 953 ZW IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS oral solution
Study: NCT03612921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v Amantadine Sulfate
Description: intra venous amantadine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet
Study: NCT00749905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fiber diet
Description: Low fiber diet for 5 days prior to colon capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular diet
Description: Regular diet until 1 day before colon capsule
Study: NCT02816983

Intervention type: RADIATION
Intervention: SBRT
Study: NCT03236090

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
Study: NCT03321682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
Study: NCT02170584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBR 953 ZW IV Placebo
Study: NCT02759068

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sounds and odors
Description: presentation of sounds and odors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sounds and odors
Description: presentation of sounds and odors
Study: NCT03321682

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: Exercises carried out using weights and involving the main muscle groups.
Study: NCT03164499

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual counselling on lifestyles
Description: Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual counselling on lifestyles
Description: Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional group counselling on lifestyles
Description: Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment.
Study: NCT00266279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Capecitabine
Description: Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21
Study: NCT02046993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart phone telemonitoring HBP + enhanced usual care
Description: Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart phone telemonitoring HBP + enhanced usual care
Description: Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
Study: NCT01462669

Intervention type: DRUG
Group type: OTHER
Intervention: 50mg Ezogabine/retigabine
Description: A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention type: DRUG
Group type: OTHER
Intervention: 100mg Ezogabine/retigabine
Description: A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention type: DRUG
Group type: OTHER
Intervention: 200mg Ezogabine/retigabine
Description: A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Intervention type: DRUG
Group type: OTHER
Intervention: 400mg Ezogabine/retigabine
Description: A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
Study: NCT03749538

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation session.
Description: Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation session.
Description: Patients with systemic autoimmune myopathies will receive or not acute transcranial direct current stimulation session.
Study: NCT04368780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Progressive Muscle Relaxation Combined With Music
Description: The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles.
Study: NCT01695356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 290-400 nm sunscreen
Description: A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
Study: NCT02832830

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: fractionated RT
Description: external beam Radiotherapy of the involved spinal bone metastasis
Study: NCT01074034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AV Therapy Assessment-B301 investigational device
Description: Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
Study: NCT04005248

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HCV IgG test
Description: An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
Study: NCT00523458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz or nevirapine
Description: Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz or nevirapine
Description: Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin.
Study: NCT01695356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 290-800 nm sunscreen
Description: A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm\^2 layer of the product as indicated on the affected areas of the face.
Study: NCT02430857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OMT
Description: Manuel osteopathic treatment of the spine
Study: NCT03095729

Intervention type: OTHER
Intervention: Neuropsychological tests
Description: A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
Study: NCT04406428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NKI followed by EBD
Description: Needle-knife incision therapy followed by endoscopic bougie dilation
Study: NCT03413462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-25
Description: HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HS-25
Description: Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.